Frontline Nivolumab Combo Succeeds in Squamous NSCLC, But Misses OS Endpoint in Nonsquamous Histology

Virginia Powers, PhD
Published: Tuesday, Dec 31, 2019
 Luiz Paz-Ares, MD, PhD, chair of the Medical Oncology Department at Hospital Doce de Octubre, and associate professor at the Universidad Complutense in Madrid, Spain

Luis Paz-Ares, MD, PhD

The first-line combination of nivolumab (Opdivo) and platinum-based chemotherapy improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) compared with chemotherapy in patients with squamous non–small cell lung cancer (NSCLC), but did not improve survival in those with nonsquamous disease, according to findings from part 2 of the final analysis of the phase III CheckMate-227 trial that was reported at the 2019 ESMO Immuno-Oncology Congress.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x